Andrew joined Tilray in March 2019 from Goldman Sachs, where he was a Managing Director and most recently served as Head of Canadian Diversified Investment Banking, which included coverage of the Canadian cannabis industry. Previously, he was a member of Goldman Sachs’ Global Healthcare Investment Banking Group in New York, where he advised on more than $200 billion in announced M&A and financing transactions, with a focus on the biopharmaceutical sector. Andrew leads Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments.
Attend Cannabis Europa London 2026
General Release
VIP Experience
BoC Awards
Working with Prohibition Partners for Cannabis Europa has been an absolute pleasure. Their dedication, exceptional professionalism, and collaborative spirit have made a meaningful difference, and we sincerely value their support.
We were truly honoured to sponsor the VIP Lounge and be part of an event that continues to set the standard for meaningful dialogue and progress in the medical cannabis industry. We left feeling excited and optimistic about the future.
